scholarly journals A CASE OF RUPTURED ANEURYSM OF THE RIGHT COMMON FEMORAL ARTERY ASSOCIATED WITH BEHÇET'S SYNDROME

1984 ◽  
Vol 45 (3) ◽  
pp. 351-356
Author(s):  
Hitoshi HANAUE ◽  
Kanji MIENO ◽  
Yoshiaki KITANO ◽  
Kunihiko FURUYA ◽  
Makoto SHISHIKURA ◽  
...  
Keyword(s):  
Femoral Artery ◽  
Common Femoral Artery ◽  
Ruptured Aneurysm ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
The Right ◽  
Behcet's Syndrome

Huge false aneurysm due to rupture of the right coronary artery in Behcet's syndrome

1982 ◽  
Vol 103 (4) ◽  
pp. 569-571 ◽  
Author(s):  
Shunichi Kaseda ◽  
Yasushi Koiwaya ◽  
Tsukasa Tajimi ◽  
Arahito Mitsutake ◽  
Hideo Kanaide ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Right Coronary Artery ◽  
False Aneurysm ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
The Right ◽  
Behcet's Syndrome

The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review

2019 ◽  
Vol 39 (6) ◽  
pp. 971-990 ◽  
Author(s):  
Alessandra Bettiol ◽  
Elena Silvestri ◽  
Gerardo Di Scala ◽  
Amedeo Amedei ◽  
Matteo Becatti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Interleukin 1 ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
The Right ◽  
Behcet's Syndrome

Behcet's syndrome

1970 ◽  
Vol 102 (1) ◽  
pp. 116-117 ◽  
Author(s):  
J. L. Fromer
Keyword(s):  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

Cutaneous Manifestations of Behçet's Syndrome

1987 ◽  
Vol 28 (4) ◽  
pp. 291 ◽  
Author(s):  
Moon Soo Yoon ◽  
Seung Hun Lee ◽  
Dong Sik Bang ◽  
Sungnack Lee
Keyword(s):  
Behçet’S Syndrome ◽  
Cutaneous Manifestations ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

scholarly journals BETTER LATE THAN NEVER: RARE CARDIOVASCULAR COMPLICATIONS OF UNDIAGNOSED BEHCET'S SYNDROME

2021 ◽  
Vol 77 (18) ◽  
pp. 2791
Author(s):  
Neiberg De Alcantara Lima ◽  
Henrique Carvalho Lima Farias ◽  
Ane Karoline Medina Neri ◽  
Danielli Lino ◽  
Isabela Thomáz Takakura Guedes ◽  
...  
Keyword(s):  
Cardiovascular Complications ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

scholarly journals Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’

2021 ◽  
pp. annrheumdis-2020-219810
Author(s):  
Jun Zou ◽  
Chen-Hong Lin ◽  
Yan Wang ◽  
Yan Shen ◽  
Jian-Long Guan
Keyword(s):  
Pilot Study ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

scholarly journals OP0028 EFFICACY OF APREMILAST FOR THE PAIN OF ORAL ULCERS ASSOCIATED WITH ACTIVE BEHÇET’S SYNDROME: 12-WEEK RESULTS FROM THE RANDOMIZED, PHASE III RELIEF STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 20.2-21
Author(s):  
G. Hatemi ◽  
A. Mahr ◽  
M. Takeno ◽  
D. Kim ◽  
M. Melikoglu ◽  
...  
Keyword(s):  
Phase Iii ◽  
Controlled Study ◽  
Behçet’S Syndrome ◽  
Research Support ◽  
Behçet's Syndrome ◽  
Oral Ulcers ◽  
Behcet’S Syndrome ◽  
Vas Scores ◽  
The Mean ◽  
Behcet's Syndrome

Background:Oral ulcers (OU) associated with Behçet’s syndrome are often painful, may interfere with the ability to eat and can negatively affect quality of life.1,2Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in the treatment of OU associated with Behçet’s syndrome in a phase III, multicenter, randomized, double-blind, placebo (PBO)-controlled study (RELIEF; BCT-002).3Objectives:To describe the efficacy of APR treatment in improving OU pain associated with Behçet’s syndrome in RELIEF.Methods:Patients were randomized (1:1) to APR 30 mg twice daily (APR 30 BID) or PBO twice daily for a 12-week PBO-controlled phase, followed by a 52-week active treatment extension. Eligible patients were ≥18 years of age and had active Behçet’s syndrome with ≥3 OU at randomization or ≥2 OU at screening and randomization and without active major organ involvement. Clinical improvement in OU was evaluated by the area under the curve for the number of OU through Week 12 (AUCWk0-12; primary efficacy endpoint) and by assessments of OU number. Patient-reported OU pain was evaluated by the 100-mm visual analogue scale (VAS). The statistical tests were 2-sided (α=0.05). The proportions of patients achieving the minimal clinically important difference (MCID) and higher rates of improvement, defined as ≥10-mm,4≥30-mm (3-fold MCID), ≥50-mm (5-fold MCID) improvements in OU pain VAS scores, respectively, were analyzed through Week 12. An ANCOVA model was used to analyze the primary endpoint and assessments of OU number and OU pain (VAS). The proportion of patients achieving improvement in OU pain VAS scores at Week 12 were summarized descriptively.Results:A total of 207 patients were randomized and received ≥1 dose of study medication (APR: n=104; PBO: n=103). At baseline, the mean (SD) number of OU was 4.2 (3.7) in the APR 30 BID group and 3.9 (2.7) in the PBO group, and the mean (SD) OU pain VAS scores were 61.2 (27.6) and 60.8 (26.9), respectively. At Week 12, significantly greater improvements were observed with APR 30 BID vs. PBO in AUCWk0-12(least-squares [LS] mean [SE]: 129.5 [15.9] vs. 222.1 [15.9];P<0.0001), number of OU (LS mean [SE]: 1.1 [0.2] vs. 2.0 [0.3];P=0.0003) and OU pain VAS scores (LS mean [SE] change from baseline: −40.7 [3.3] vs. −15.9 [3.3];P<0.0001). The proportion of patients who achieved the MCID of ≥10-mm improvement in OU pain VAS scores at Week 12 was greater with APR 30 BID vs. PBO; this pattern was also observed for the higher 3- and 5-fold improvements in MCID (Figure 1). Greater proportions of APR 30 BID vs. PBO patients achieved ≥10-mm and ≥30-mm improvements in OU pain VAS scores over 12 weeks. Notably, greater achievement of ≥50-mm improvement in OU pain VAS scores was observed with APR 30 BID vs. PBO as early as Week 1 and maintained up to Week 12 (Figure 2).Conclusion:For patients with active Behçet’s syndrome, APR 30 BID provided significantly greater improvements vs. PBO in OU number and OU pain at Week 12, including the greater proportion of patients achieving MCID and 3- and 5-fold MCID of OU pain in the APR 30 BID group vs. the PBO group. These results indicate a clinically meaningful treatment effect of APR 30 BID on the OU associated with Behçet’s syndrome.References:[1]Kokturk A.Patholog Res Int. 2012;2012:690390.[2]Hatemi G, et al.Ann Rheum Dis. 2008;67:1656-1662.[3]Hatemi G, et al.N Engl J Med. 2019;381:1918-1928. 4. Dworkin RH, et al.J Pain. 2008;9:105-121.Disclosure of Interests:Gulen Hatemi Grant/research support from: BMS, Celgene Corporation, Silk Road Therapeutics – grant/research support, Consultant of: Bayer, Eli Lilly – consultant, Speakers bureau: AbbVie, Mustafa Nevzat, Novartis, UCB – speaker, Alfred Mahr Consultant of: Celgene, Speakers bureau: Roche, Chugai, Mitsuhiro Takeno Speakers bureau: Esai, Tanabe-Mitsubishi – speaker; Celgene Corporation – advisory board, Doyoung Kim: None declared, Melike Melikoglu: None declared, Sue Cheng Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Shannon McCue Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Sven Richter Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Michele Brunori Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Maria Paris Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Mindy Chen Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of the conduct, Yusuf Yazici Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant, Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant

Sign in / Sign up

Export Citation Format

Share Document